BioSpace News Archive

CorMedix Inc. announced financial results for the third quarter and nine months ended September 30, 2023 and provided an update on recent business events.

Icosavax, Inc. (Nasdaq: ICVX) today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Miromatrix Medical Inc. (Nasdaq: MIRO) (the “Company”), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today reported third quarter 2023 financial results.

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter ended September 30, 2023, and provided a corporate update.

SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and nine months ended September 30, 2023 and provides a business update.

Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) (“Perimeter” or the “Company”) – a commercial-stage medical technology company – today reported financial results for its third quarter ended September 30, 2023 and provided a corporate update.

Illumina, Inc. announced that its executives will be speaking at the following investor conferences.

Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2023.

Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”) today announced financial results for the three and nine months ended September 30, 2023 and highlighted recent corporate updates.